International Journal of Pharmaceutical Research and Development

ISSN Print: 2664-6862
ISSN Online: 2664-6870
Impact Factor: RJIF 8.55
IJPRD 2025; 7(2): 835-841
www.pharmaceuticaljournal.net
Received: 02-10-2025
Accepted: 04-11-2025

Chetna D Kapgate
Priyadarshini J. L. College of Pharmacy, Electronic Zone Building, MIDC, Hingna Road, Nagpur, Maharashtra, India

Dr. Dinesh P Kawade
Priyadarshini J. L. College of Pharmacy, Electronic Zone Building, MIDC, Hingna Road, Nagpur, Maharashtra, India

Mahima R Bijewar
Priyadarshini J. L. College of Pharmacy, Electronic Zone Building, MIDC, Hingna Road, Nagpur, Maharashtra, India

Achal Gadhwale
Priyadarshini J. L. College of Pharmacy, Electronic Zone Building, MIDC, Hingna Road, Nagpur, Maharashtra, India

Aditi Tayde
Priyadarshini J. L. College of Pharmacy, Electronic Zone Building, MIDC, Hingna Road, Nagpur, Maharashtra, India

Corresponding Author:
Chetna D Kapgate
Priyadarshini J. L. College of Pharmacy, Electronic Zone Building, MIDC, Hingna Road, Nagpur, Maharashtra, India

Integrating bronchodilators and corticosteroids: A review of combination drug strategies for asthma

Chetna D Kapgate, Dinesh P Kawade, Mahima R Bijewar, Achal Gadhwale and Aditi Tayde

DOI: https://www.doi.org/10.33545/26646862.2025.v7.i2i.250

Abstract
Asthma is a chronic inflammatory airway disease characterized by reversible airflow obstruction, bronchial hyperresponsiveness, and episodic exacerbations. Achieving optimal control requires addressing both acute bronchoconstriction and persistent airway inflammation. This review focuses on the therapeutic importance of the Levosalbutamol-Beclomethasone dipropionate combination as an effective double drug strategy for asthma management. Levosalbutamol, an enantiomerically pure and highly selective short-acting β2-agonist (SABA), provides rapid bronchodilation with fewer β2-mediated adverse effects compared to racemic salbutamol. Beclomethasone dipropionate, a widely used inhaled corticosteroid (ICS), delivers potent local anti-inflammatory action, reducing airway edema, mucus production, and the frequency of exacerbations. Together, these agents offer a complementary mechanism: Levosalbutamol immediately relieves bronchospasm, while Beclomethasone dipropionate provides sustained control of underlying inflammation.
The concurrent or fixed-dose use of this combination is particularly beneficial for patients with mild to moderate persistent asthma who require both fast symptomatic relief and long-term control. Clinical evidence indicates improved peak expiratory flow, reduced nocturnal symptoms, and decreased reliance on rescue medication compared to monotherapy. This combination also fits well within stepwise asthma management guidelines, where ICS-SABA double therapy is recommended for individuals who remain uncontrolled with single-agent treatment. Despite established efficacy, barriers such as inconsistent adherence, incorrect inhaler technique, and variable individual response continue to influence treatment outcomes. Enhancing patient education, refining inhaler technologies, and tailoring therapy to individual phenotypes may improve overall effectiveness.

Keywords: Double drug strategy, ICS-SABA, asthma management

Introduction
Asthma is a prevalent chronic respiratory disorder characterized by persistent airway inflammation, episodic bronchoconstriction, and variable airflow limitation. Despite significant advancements in diagnosis and treatment, asthma continues to affect millions of people worldwide and remains a major cause of morbidity, reduced quality of life, and healthcare burden. The disease's complex and heterogeneous nature, influenced by genetic, environmental, and immunological factors, contributes to challenges in achieving consistent symptom control and preventing exacerbations. Consequently, developing therapeutic strategies that address the multifactorial pathophysiology of asthma is essential for effective long-term management [1].
Pharmacological therapy for asthma primarily targets two critical components: acute bronchoconstriction and chronic airway inflammation. Bronchodilators, particularly β2-adrenergic agonists, play a vital role in rapidly relieving airflow obstruction through relaxation of airway smooth muscles [1, 3]. On the other hand, inhaled corticosteroids (ICS) are the most effective anti-inflammatory agents available, capable of reducing airway edema, mucus hypersecretion, inflammatory cell infiltration, and long-term airway remodeling. Although both classes provide important therapeutic benefits individually, monotherapy often fails to deliver adequate control in many patients, especially those with moderate or persistent symptoms [4].

The integration of bronchodilators with corticosteroids has become a central strategy in modern asthma management. Combination therapy provides a synergistic effect bronchodilators enhance the distribution of corticosteroids within the airways, while ICS increase β2-receptor sensitivity, leading to more effective and sustained bronchodilation. This dual approach has consistently demonstrated improved lung function, reduced symptom frequency, enhanced quality of life, and a lower risk of exacerbations compared with single-drug therapy. Moreover, fixed-dose combinations and improved inhaler technologies have further strengthened adherence and therapeutic outcomes [7].

Given the expanding evidence base and evolving clinical guidelines, a comprehensive understanding of combination therapy is crucial. This review analyzes the pharmacological rationale, clinical benefits, safety considerations, and practical applications of integrating bronchodilators and corticosteroids, emphasizing their continued relevance in achieving optimal asthma control.

Pathophysiology of Asthma

Asthma is a complex, heterogeneous respiratory disorder characterized by chronic airway inflammation, reversible airflow limitation, and episodic bronchoconstriction. Its pathophysiology involves multiple cellular and molecular processes that interact to produce the characteristic symptoms of wheezing, dyspnea, cough, and chest tightness. Understanding these underlying mechanisms is essential for optimizing therapeutic strategies, particularly combination treatments that address both bronchospasm and inflammation [3].

1. Airway Inflammation

Chronic airway inflammation is the hallmark of asthma and contributes significantly to disease persistence and severity. This inflammation results in swelling of the bronchial mucosa, increased vascular permeability, and excessive mucus secretion. The inflammatory response is driven by a variety of mediators, including cytokines, chemokines, and lipid-derived substances such as leukotrienes and prostaglandins. Persistent inflammation narrows the airway lumen, increases airway sensitivity, and plays a central role in exacerbation frequency. Inflammatory processes also increase the demand for corticosteroid therapy, making the rationale for integrating anti-inflammatory drugs within asthma management essential [1, 3].



Fig 1: Pathophysiology of asthma

2. Bronchial Hyperresponsiveness

Bronchial hyperresponsiveness (BHR) refers to the exaggerated narrowing of airways in response to stimuli such as allergens, pollutants, cold air, or exercise. Structural changes and chronic inflammation enhance smooth muscle contractility, making the airways highly reactive. BHR contributes to the episodic and variable nature of asthma symptoms and is a key target for bronchodilator therapy, especially β2-agonists like levosalbutamol, which help reduce acute bronchospasm.

3. Role of Immune Cells

Eosinophils: Eosinophils are closely associated with allergic asthma, releasing toxic granule proteins, cytokines (IL-5, IL-13), and reactive oxygen species that damage airway epithelium, increase mucus production, and sustain inflammation.

Mast Cells: Mast cells are activated by allergens via IgE-mediated pathways and release histamine, tryptase, and leukotrienes upon degranulation. These mediators contribute to acute bronchoconstriction, vascular leakage, and airway edema.

T-Lymphocytes: T-helper 2 (Th2) lymphocytes orchestrate the inflammatory response by producing cytokines such as IL-4, IL-5, and IL-13, promoting IgE synthesis, eosinophil activation, and mucus hypersecretion. In non-allergic asthma, Th17 cells and neutrophils may dominate, contributing to corticosteroid resistance [3].

4. Airway Remodeling

Chronic inflammation leads to irreversible structural changes known as airway remodeling. Key features include subepithelial fibrosis, airway smooth muscle hypertrophy and hyperplasia, goblet cell hyperplasia, and thickening of

the basement membrane. These structural changes decrease the elasticity of airways, contribute to fixed airflow obstruction, and reduce responsiveness to therapy. Early and adequate anti-inflammatory treatment, particularly with inhaled corticosteroids, is critical in limiting airway remodeling [1, 3].

Need and Rationale for Combination Therapy

The management of asthma requires addressing both acute bronchoconstriction and chronic airway inflammation two interrelated but distinct components of the disease. While monotherapy with either a bronchodilator or an inhaled corticosteroid (ICS) provides partial benefits, many patients fail to achieve optimal control when treated with a single agent. Combination therapy integrating bronchodilators and corticosteroids has therefore become a cornerstone of modern asthma management due to its superior clinical effectiveness and mechanistic synergy [7, 13].

1. Limitations of Monotherapy (ICS Alone or Bronchodilator Alone)

Monotherapy with inhaled corticosteroids effectively reduces inflammation, improves lung function, and decreases exacerbation frequency. However, ICS alone often fails to provide rapid relief of acute bronchoconstriction, limiting its usefulness during sudden symptom worsening.

Similarly, bronchodilators such as β2-agonists provide immediate symptom relief but do not address the underlying inflammatory process. Prolonged use of bronchodilators alone may even worsen asthma control by masking uncontrolled inflammation and causing receptor desensitization. These limitations highlight the need for a combined approach that targets both symptom relief and long-term disease control.

2. Dual Targeting of Acute and Chronic Components

Asthma pathology involves both acute bronchospasm and chronic inflammation. Combining a bronchodilator with an ICS allows simultaneous targeting of these two processes. Bronchodilators offer rapid airway smooth muscle relaxation, improving airflow, while corticosteroids suppress the inflammatory cascade responsible for edema, mucus hypersecretion, and airway hyperresponsiveness. This dual targeting results in more comprehensive disease control than monotherapy.

3. Synergistic Mechanisms of Bronchodilators and Corticosteroids

Bronchodilators and corticosteroids exhibit true pharmacologic synergy. Corticosteroids enhance β2-receptor sensitivity and upregulate receptor expression, making bronchodilators more effective. Conversely, bronchodilators improve corticosteroid actions by increasing glucocorticoid receptor nuclear translocation and reducing cytokine production. This bidirectional enhancement results in improved bronchodilation, reduced inflammation, and greater overall symptom control.

4. Improved Drug Deposition and Receptor Responsiveness

Bronchodilators relax the airway smooth muscle, increasing airway diameter and enhancing the deposition of inhaled corticosteroids deeper into the bronchial tree. Better ICS penetration improves anti-inflammatory activity and helps prevent airway remodeling. At the same time, corticosteroids maintain and restore β2-receptor responsiveness, preventing tolerance or reduced efficacy during long-term bronchodilator use. This enhances the reliability and sustainability of therapy.

Bronchodilators in Asthma Management

Bronchodilators are essential agents in asthma therapy because they directly relieve bronchoconstriction a hallmark symptom responsible for wheezing, breathlessness, and airflow limitation. They act by relaxing airway smooth muscles and improving ventilation, thereby offering rapid symptomatic control or long-term maintenance depending on their pharmacological class [4, 5].

1. Short-Acting β_2 Agonists (SABA)

SABAs such as salbutamol (albuterol) and levosalbutamol provide rapid bronchodilation within minutes. They are primarily used for:

- Immediate relief of acute bronchospasm
- Pre-exercise prophylaxis
- Rescue therapy during exacerbations

Their onset is usually within 3-5 minutes, with duration lasting 4-6 hours [4, 5].

2. Long-Acting β_2 Agonists (LABA):

LABAs, including salmeterol and formoterol, provide 12-24 hours of bronchodilation.

They are used for:

- Long-term control of persistent asthma.
- Night-time asthma symptoms.
- Combination use with inhaled corticosteroids (ICS).

Importantly, LABAs must not be used as monotherapy in asthma; they are always combined with ICS to prevent deterioration and ensure anti-inflammatory coverage [5].

3. Mechanism of Action of β_2 Agonists

Both SABA and LABA act by:

1. Cyclase via Gs-proteins.
2. Stimulating β_2-adrenergic receptors on airway smooth muscle.
3. Activating adenylate Increasing cyclic AMP (cAMP) levels.
4. Activating protein kinase A, leading to:

- Smooth muscle relaxation
- Inhibition of mast cell mediator release
- Enhanced mucociliary clearance [5]

This cascade results in rapid opening of airways and improved airflow.

4. Focus on Levosalbutamol Pharmacology

Levosalbutamol (R-salbutamol) is the pharmacologically active enantiomer of racemic salbutamol.

Key pharmacological features include:

- Higher β_2 selectivity, resulting in more efficient bronchodilation
- Greater affinity for β_2 receptors versus the S-isomer
- Reduced stimulation of non-target receptors

- Lower risk of tachycardia, tremors, and metabolic disturbances
- Faster onset and more predictable dose-response relationship
- Superior bronchodilation at half the dose of racemic salbutamol
- As-needed therapy in combination with ICS

Levosalbutamol is available in inhalation, nebulization, and metered-dose formulations, often used in acute asthma, pediatric exacerbations, and patient intolerant to racemic salbutamol.

Table 1: Advantages Over Racemic Salbutamol [6]

Parameter	Levosalbutamol R Enantiomer	Racemic Salbutamol (R+S)
Active bronchodilator component	Only R-isomer	Contain inactive/ non beneficial S-isomer
Bronchodilation potency	Higher	Moderate
Side effects	Lower	Higher due to S-isomer
Airway hyper responsiveness	Incidence (tachycardia, tremor)	S-isomer may enhance inflammation
Dose requirement	Lower effective dose	Higher dose needed
Onset of action	Faster and more consistent	Slightly slower

The S-isomer in racemic salbutamol does not contribute to bronchodilation and may cause bronchial hyper-responsiveness, oxidative stress, and tolerance. Because of this, levosalbutamol often offers improved safety and efficacy, especially in sensitive populations [6].

Inhaled Corticosteroids (ICS)

1. Pharmacological Action

Inhaled corticosteroids are the foundation of long-term asthma management due to their ability to directly target airway inflammation. ICS act by binding to intracellular glucocorticoid receptors in epithelial cells, macrophages, eosinophils, and T-lymphocytes. After receptor activation, the complex translocates to the nucleus and modulates gene transcription, resulting in downregulation of pro-inflammatory mediators such as IL-4, IL-5, IL-13, and TNF-α. ICS also inhibit the release of inflammatory enzymes, reduce mucosal swelling, and restore β_2-adrenergic receptor responsiveness, thereby enhancing the effectiveness of bronchodilators. Collectively, these actions reduce symptoms, improve lung function, and prevent asthma exacerbations [15].

2. Anti-Inflammatory and Anti-Remodeling Effects

ICS not only suppress airway inflammation but also provide structural protection against chronic remodeling changes. Their anti-inflammatory effects include reducing eosinophil activation, decreasing chemokine release, inhibiting mast cell activity, and minimizing mucus gland hypersecretion. Long-term use helps reduce airway hyperresponsiveness.

Anti-remodeling effects include:

- Inhibition of fibroblast proliferation and collagen deposition
- Reduction in airway smooth muscle hypertrophy
- Restoration of epithelial integrity
- Prevention of thickening of the basement membrane

These actions help slow or reverse the structural progression of asthma, contributing to improved long-term disease control.

3. Focus on Beclomethasone Dipropionate Properties

Beclomethasone dipropionate (BDP) is a widely used ICS known for its potent anti-inflammatory action and favorable safety profile. It is formulated as a prodrug, converted in the lungs to its active metabolite beclomethasone-17-monopropionate (B-17-MP), which has significantly higher glucocorticoid receptor affinity. Extra-fine particle formulations enhance deposition in both central and peripheral airways, making BDP particularly effective in treating small airway inflammation. Its low systemic bioavailability and extensive first-pass metabolism contribute to reduced systemic adverse effects.

4. Safety and Dose Considerations

ICS, including BDP, are generally safe when used at recommended doses. Local adverse effects may include oropharyngeal candidiasis, hoarseness, and throat irritation, which can be minimized by rinsing the mouth or using a spacer device. Systemic effects such as adrenal suppression, decreased bone mineral density, and growth retardation in children are dose-dependent and uncommon at low-to-medium doses.

Typical adult dosing ranges:

- Low dose: 100-200 µg/day
- Medium dose: 200-400 µg/day
- High dose: >400 µg/day

The extra-fine BDP formulations allow effective control at comparatively lower doses, improving safety while maintaining therapeutic benefit.

Levosalbutamol-Beclomethasone Dipropionate Combination

The combination of Levosalbutamol and Beclomethasone dipropionate (BDP) is widely used in asthma because it targets both the immediate symptoms and the underlying inflammation. Levosalbutamol is a fast-acting bronchodilator that quickly relaxes the airway muscles and provides relief during episodes of breathlessness. BDP, on the other hand, is an inhaled corticosteroid that controls long-term inflammation, reduces swelling in the airways, and helps prevent future asthma attacks [7, 15].

1. **Mechanistic Synergy:** These two drugs work better together than alone. Levosalbutamol opens the airways, allowing BDP to reach deeper parts of the lungs, improving its anti-inflammatory action. Meanwhile, BDP increases the sensitivity of β_2-receptors, making Levosalbutamol more effective even after repeated use.
2. **Clinical Benefits:** Using both drugs results in faster symptom relief, better daily asthma control, fewer night-time symptoms, and reduced need for rescue inhalers. Patients often experience fewer exacerbations and improved quality of life. Faster relief of wheezing, chest tightness, and dyspnea due to rapid-onset bronchodilation. Lower doses of ICS may be sufficient

because of improved airway penetration and synergy. Clinical studies support faster improvement in symptoms [15].

3. **Dose Forms and Delivery Systems:** The combination can be given through separate inhalers, metered-dose inhalers (MDIs), dry-powder inhalers (DPIs), or nebulizers. Many patients use Levosalbutamol for quick relief and BDP daily for maintenance therapy. Using properly designed inhaler devices ensures optimal lung deposition, reduces oropharyngeal losses, and improves overall treatment effectiveness.
4. **Evidence from Clinical Studies:** Studies show that combining a bronchodilator with an inhaled steroid is more effective than using either drug alone. Research with Levosalbutamol and BDP demonstrates improved lung function and better symptom control [7].
5. **Safety Profile:** Side effects are generally mild. Levosalbutamol may cause slight tremor or palpitations, while BDP can lead to throat irritation or hoarseness. Rinsing the mouth and correct inhaler technique reduce these effects.

Clinical Efficacy and Guideline Recommendations

Major asthma guidelines recommend using an inhaled corticosteroid (ICS) together with a bronchodilator rather than relying on a bronchodilator alone. The Global Initiative for Asthma (GINA) now advises that ICS-containing treatment should be used from the earliest stages of asthma care to reduce the risk of severe exacerbations. These recommendations highlight that combining agents such as Levosalbutamol and Beclomethasone Dipropionate provides more consistent symptom control and better long-term outcomes than monotherapy approaches [2].

1. When to start double therapy: Start ICS + bronchodilator when a patient's symptoms are not controlled by as-needed reliever alone or when they have frequent symptoms (for example, symptoms on most days or waking with asthma ≥ once per week). For many patients, even those with mild intermittent symptoms, adding ICS (either regularly or whenever a reliever is used) is safer than SABA-only treatment [2, 16].

2. Indications by severity

- **Mild asthma:** Use low-dose ICS regularly or consider as-needed low-dose ICS with SABA/ICS reliever depending on guideline and patient preference.
- **Moderate persistent:** Regular low-to-medium dose ICS plus a bronchodilator is recommended to improve control and prevent exacerbations.
- **Severe/persistent:** Patients uncontrolled on medium-dose ICS + bronchodilator need specialist assessment and step-up options.

3. Pediatrics vs adults: Guidelines apply the same principle: avoid SABA-only treatment in children >5 years—use ICS-containing therapy for safety. Dosing and device choice differ by age (spacers, mask use for young children), and growth should be monitored in children on long-term higher-dose ICS [2].

Limitations and Challenges

1. **Poor Adherence:** One of the biggest challenges in asthma treatment is poor adherence to inhaled medications. Many patients forget daily doses, do not understand the importance of regular inhaled corticosteroid (ICS) use, or stop treatment when symptoms improve. This leads to poor asthma control, more frequent attacks, and decreased effectiveness of combination therapy such as Levosalbutamol + Beclomethasone dipropionate.
2. **Inhaler Technique Errors:** Incorrect inhaler technique is a major reason why patients do not receive the full benefit of their medication. Common mistakes include incorrect timing of inhalation, not shaking the inhaler, breathing too fast or too slow, and not using spacers when required. These errors reduce drug deposition in the lungs and can cause overuse of rescue inhalers due to inadequate relief. Regular training, demonstrations, and reassessment of inhaler technique are essential to ensure patients achieve optimal therapeutic outcomes.
3. **Variability in Patient Response:** Asthma is a highly variable disease, and patients often respond differently to the same medication. Factors such as age, genetic background, severity of inflammation, environmental triggers, and comorbidities (like allergies or obesity) influence how well a patient responds to Levosalbutamol-BDP therapy. This variability sometimes requires dose adjustments or switching to alternative inhalers.
4. **Steroid-Related Concerns:** Although inhaled corticosteroids are much safer than oral steroids, some patients worry about long-term side effects. Potential issues include throat irritation, hoarseness, oral candidiasis, and in higher doses systemic effects like adrenal suppression or reduced growth in children. These concerns may reduce adherence if not properly explained by healthcare providers. Clear counseling on proper inhaler use, mouth rinsing, and dose optimization can greatly reduce these risks and improve patient confidence in therapy.

Future Perspectives

1. Precision and Phenotype-Based Therapy

Asthma is now understood as a group of different disease types rather than one single disorder. Future treatment will focus on precision therapy, where medications are chosen based on the patient's specific phenotype such as eosinophilic asthma, allergic asthma, or neutrophilic inflammation. Matching Levosalbutamol BDP or other combinations to individual patient characteristics can improve control and reduce unnecessary steroid exposure [14].

2. Biomarkers for Patient Selection

Biomarkers are becoming important tools for predicting which patients will respond best to inhaled corticosteroids. Markers such as blood eosinophil count, FeNO (fractional exhaled nitric oxide), serum IgE, and periostin levels can help identify inflammation patterns. In the future, these biomarkers may guide decisions such as when to start ICS, when to escalate doses, and which patients will benefit the most from combination therapies.

3. Digital Inhalers, AI Monitoring, and Dosing Optimization

Modern inhalers are increasingly equipped with sensors that track inhalation technique, frequency of use, and timing.

When paired with mobile apps and AI-based systems, these digital inhalers can remind patients to take medication, detect errors in technique, and provide personalized feedback. AI tools may also analyze symptoms, triggers, and adherence patterns to optimize dosing schedules and predict upcoming exacerbations before they occur [16].

4. Research Gaps

Despite progress, several gaps remain. More studies are needed to compare Levosalbutamol BDP with other ICS-bronchodilator combinations. Research is also required to better understand long-term safety, effects on small airways, and outcomes in children and elderly patients. Additionally, low-cost digital tools and real-world studies are needed to ensure these advances are accessible and effective in everyday clinical practice.

Conclusion

Asthma is a multifactorial and heterogeneous respiratory condition driven by chronic airway inflammation, bronchial hyperresponsiveness, and fluctuating airflow limitation. Although numerous therapeutic options are available, monotherapy with either bronchodilators or corticosteroids often fails to provide comprehensive and sustained control. This review synthesizes the current scientific and clinical evidence supporting the integration of bronchodilators and inhaled corticosteroids (ICS) as a unified therapeutic strategy, demonstrating how this approach effectively targets both the acute and chronic mechanisms underlying asthma. Accumulated research shows that combination therapy significantly enhances clinical outcomes, symptom management, and long-term disease control compared with single-agent treatment.

Bronchodilators particularly β_2-agonists offer rapid relief from bronchoconstriction by inducing smooth muscle relaxation. Conversely, corticosteroids address the persistent inflammatory component of asthma by suppressing cytokine release, reducing eosinophilic activity, and mitigating structural airway changes. When administered together, these drugs operate in a synergistic manner. Corticosteroids enhance β_2-receptor expression and function, preventing receptor downregulation and increasing responsiveness to bronchodilator therapy. Bronchodilators, in turn, facilitate corticosteroid penetration into airway tissues, thereby amplifying their anti-inflammatory potential. This reciprocal pharmacological reinforcement explains the superior therapeutic benefit of combination therapy.

International bodies such as GINA and the NHLBI strongly advocate fixed-dose ICS-LABA combinations for moderate to severe persistent asthma and increasingly recommend earlier introduction when monotherapy does not achieve adequate control. These recommendations are supported by extensive clinical evidence demonstrating improvements in lung function parameters, reduced nocturnal symptoms, fewer exacerbations, lower hospitalization rates, and reduced need for rescue medications. Furthermore, combination inhalers enhance patient adherence by simplifying dosing regimens and minimizing device burden—an important consideration given the persistent challenges of non-adherence and inhaler misuse in asthma management.

Within this therapeutic landscape, the combination of levosalbutamol and beclomethasone dipropionate represents a particularly valuable option. Levosalbutamol the active R-isomer of salbutamol provides efficient bronchodilation with a reduced incidence of adverse effects such as tremors and tachycardia. Beclomethasone dipropionate, known for its strong receptor affinity and excellent pulmonary deposition, delivers potent anti-inflammatory action even at low doses, enhancing both efficacy and safety. Their combined use delivers rapid symptomatic relief alongside sustained control of underlying inflammation, making this combination suitable for both acute episodes and long-term maintenance therapy.

Despite its strengths, combination therapy is not without challenges. Chronic ICS exposure may still cause systemic effects, including potential adrenal suppression, oral candidiasis, decreased bone mineral density, and growth-related concerns in pediatric populations. Excessive reliance on bronchodilators may also obscure poorly controlled inflammation. Moreover, variability in therapeutic responses—driven by genetic, phenotypic, and environmental factors—underscores the need for individualized, stepwise management. Regular assessment of symptoms, lung function, and adherence remains essential to optimize outcomes and prevent unnecessary escalation of therapy.

Emerging trends in asthma research emphasize personalized, phenotype-driven treatment strategies. Biomarkers such as exhaled nitric oxide, blood eosinophils, periostin, and sputum inflammatory profiles are increasingly useful in predicting responsiveness to corticosteroid-based therapies. Pharmacogenomic insights are also advancing the field, offering the potential to tailor bronchodilator and corticosteroid therapy based on genetic determinants of drug metabolism and receptor sensitivity. Such precision approaches may help maximize benefits while reducing adverse effects.

Technological advances offer further opportunities to refine combination therapy. Smart inhalers equipped with digital sensors enable precise monitoring of medication use, inhaler technique, and adherence patterns. Integration of artificial intelligence and predictive algorithms may facilitate early detection of exacerbation risk, optimize dosing schedules, and guide real-time clinical decision-making. These innovations have the potential to significantly improve patient engagement and long-term disease stability.

In conclusion, the integration of bronchodilators and inhaled corticosteroids remains a cornerstone of contemporary asthma management. The combination provides rapid relief, sustained anti-inflammatory activity, improved adherence, and better overall control of the disease. As highlighted in this review, combinations such as levosalbutamol and beclomethasone dipropionate exemplify the therapeutic value of dual-mechanism strategies. Ongoing developments in precision medicine, pharmacogenomics, and digital health technologies will continue to strengthen and refine this approach. Ultimately, the evolution of combination therapy guided by robust scientific evidence and tailored to individual patient needs promises to deliver more consistent and durable asthma control across diverse patient populations.

References

1. Rang HP, Dale MM, Ritter JM, Flower R. Rang & Dale's pharmacology. 9th ed. London: Elsevier; 2019.
2. GINA Scientific Committee. Global strategy for asthma management and prevention. Updated annual edition.

Fontana (WI): Global Initiative for Asthma (GINA); [year unknown].
3. Barnes PJ, Drazen JM, Rennard S, Thomson NC. Asthma and COPD: basic mechanisms and clinical management. 2nd ed. London: Elsevier; 2015.
4. Barnes PJ. Scientific rationale for using a single inhaler for asthma control. Eur Respir J. 2007;29(3):587-595.
5. Nelson HS. β2-Agonists and asthma: the risks and benefits. Chest. 2006;130(4):1153-1162.
6. Derom E, Louis R, Liistro G, *et al*. Dose-response study of inhaled levosalbutamol vs racemic salbutamol. Pulm Pharmacol Ther. 2004;17(3):155-160.
7. Papi A, Brightling C, Pedersen SE, Reddel HK. ICS-SABA combination therapy for mild asthma. N Engl J Med. 2019;381:1720-1730.
8. Hekking PP, Wener RR, Amelink M, *et al*. Asthma phenotypes and personalized therapy. J Allergy Clin Immunol. 2015;136(4):859-870.
9. Koda-Kimble MA, Young LY, Kradjan WA, Guglielmo BJ, editors. Applied therapeutics: the clinical use of drugs. 11th ed. Philadelphia: Wolters Kluwer; 2020.
10. Chung KF, Wenzel SE, Brozek JL, *et al*. Asthma: disease mechanisms and therapeutic strategies. Pharmacol Ther. 2020;207:107447.
11. Usmani OS. Small airway dysfunction in asthma: role of extra-fine ICS. J Allergy Clin Immunol. 2014;133(2):343-356.
12. Improving inhaler adherence with digital devices. Pharmacy Times. 2023;1:1-3.
13. National Asthma Education and Prevention Program (NAEPP). Expert panel report 3: guidelines for diagnosis and management of asthma. Bethesda (MD): National Institutes of Health; 2008.
14. Nature Medicine Editorial Board. New trends in personalized asthma therapy. Nat Med. 2021;27:1-5.
15. Giembycz MA, Newton R. How corticosteroids suppress inflammation: synergistic interactions with β2-agonists. Pulm Pharmacol Ther. 2006;19(2):67-80.
16. Reddel HK, Bacharier LB, Bateman ED, *et al*. Global Initiative for Asthma (GINA) 2023: updated treatment recommendations. Eur Respir J. 2023;62(3):2201989.